NASDAQ:APTO - Lorus Therapeutics Stock Price, Price Target & More

$3.41 -0.19 (-5.28 %)
(As of 04/22/2018 08:05 AM ET)
Previous Close$3.41
Today's Range$3.39 - $3.6327
52-Week Range$0.78 - $3.97
Volume223,461 shs
Average Volume307,635 shs
Market Capitalization$104.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32

About Lorus Therapeutics (NASDAQ:APTO)

Lorus Therapeutics logoAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828

Debt

Debt-to-Equity RatioN/A
Current Ratio6.72%
Quick Ratio6.72%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.39 per share
Price / Book8.74

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-11,660,000.00
Net MarginsN/A
Return on Equity-123.32%
Return on Assets-106.81%

Miscellaneous

Employees23
Outstanding Shares30,700,000

How to Become a New Pot Stock Millionaire

Lorus Therapeutics (NASDAQ:APTO) Frequently Asked Questions

What is Lorus Therapeutics' stock symbol?

Lorus Therapeutics trades on the NASDAQ under the ticker symbol "APTO."

How were Lorus Therapeutics' earnings last quarter?

Lorus Therapeutics, Inc. (NASDAQ:APTO) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.07. View Lorus Therapeutics' Earnings History.

What price target have analysts set for APTO?

4 Wall Street analysts have issued 1 year price objectives for Lorus Therapeutics' shares. Their predictions range from $6.00 to $7.00. On average, they expect Lorus Therapeutics' stock price to reach $6.3333 in the next year. View Analyst Ratings for Lorus Therapeutics.

Who are some of Lorus Therapeutics' key competitors?

Who are Lorus Therapeutics' key executives?

Lorus Therapeutics' management team includes the folowing people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

Has Lorus Therapeutics been receiving favorable news coverage?

Media coverage about APTO stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lorus Therapeutics earned a news impact score of 0.07 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.49 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Lorus Therapeutics?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lorus Therapeutics' stock price today?

One share of APTO stock can currently be purchased for approximately $3.41.

How big of a company is Lorus Therapeutics?

Lorus Therapeutics has a market capitalization of $104.69 million. The biotechnology company earns $-11,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Lorus Therapeutics employs 23 workers across the globe.

How can I contact Lorus Therapeutics?

Lorus Therapeutics' mailing address is 5955 AIRPORT ROAD SUITE 228, MISSISSAUGA A6, L4V 1R9. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]


MarketBeat Community Rating for Lorus Therapeutics (APTO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Lorus Therapeutics and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Lorus Therapeutics (NASDAQ:APTO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Lorus Therapeutics in the last 12 months. Their average twelve-month price target is $6.3333, suggesting that the stock has a possible upside of 85.73%. The high price target for APTO is $7.00 and the low price target for APTO is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.3333$6.00$6.00$7.00
Price Target Upside: 85.73% upside86.92% upside233.33% upside389.51% upside

Lorus Therapeutics (NASDAQ:APTO) Consensus Price Target History

Price Target History for Lorus Therapeutics (NASDAQ:APTO)

Lorus Therapeutics (NASDAQ:APTO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018Roth CapitalSet Price TargetBuy$6.00LowView Rating Details
4/16/2018HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
11/15/2017Canaccord GenuitySet Price TargetBuy$7.00N/AView Rating Details
6/8/2017Rodman & RenshawInitiated CoverageNeutral -> NeutralHighView Rating Details
11/16/2016Royal Bank of CanadaLower Price TargetOutperform$18.00 -> $12.00N/AView Rating Details
6/9/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Lorus Therapeutics (NASDAQ:APTO) Earnings History and Estimates Chart

Earnings by Quarter for Lorus Therapeutics (NASDAQ:APTO)

Lorus Therapeutics (NASDAQ:APTO) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.51 EPS
Next Year EPS Consensus Estimate: $-0.5 EPS

Lorus Therapeutics (NASDAQ APTO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.13)($0.11)ViewN/AView Earnings Details
8/8/2017Q2($0.18)($0.11)ViewListenView Earnings Details
5/11/2017Q1 2017($0.19)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.19)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.36)($0.24)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.32)($0.36)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.30)($0.31)ViewN/AView Earnings Details
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.31)($0.22)ViewN/AView Earnings Details
5/5/2015Q1 2015($0.31)($0.25)ViewN/AView Earnings Details
3/3/2015Q4 2014($0.31)($0.25)ViewN/AView Earnings Details
11/5/2014Q3 2014($0.32)ViewN/AView Earnings Details
7/15/2014Q2 2014($0.24)($0.48)ViewN/AView Earnings Details
4/10/2014Q1 2014($0.72)($0.48)ViewN/AView Earnings Details
1/7/2014Q4 2013($0.72)ViewN/AView Earnings Details
10/15/2013Q3 2013($0.36)ViewN/AView Earnings Details
7/15/2013Q2 2013($0.36)ViewN/AView Earnings Details
4/12/2013Q1 2013($0.36)ViewN/AView Earnings Details
1/14/2013Q4 2012($0.48)ViewN/AView Earnings Details
10/15/2012Q3 2012($0.36)ViewN/AView Earnings Details
8/8/2012Q2 2012$0.60ViewN/AView Earnings Details
4/12/2012Q1 2012($0.58)ViewN/AView Earnings Details
1/13/2012Q4 2011($0.82)ViewN/AView Earnings Details
11/11/2011Q3 2011($0.76)ViewN/AView Earnings Details
8/26/2011Q2 2011($0.73)ViewN/AView Earnings Details
1/14/2011Q4 2010($1.34)ViewN/AView Earnings Details
10/15/2010Q3 2010($1.38)ViewN/AView Earnings Details
8/30/2010Q2 2010($2.16)ViewN/AView Earnings Details
1/14/2009Q4 2008$4.41ViewN/AView Earnings Details
10/9/2008Q3 2008$3.24ViewN/AView Earnings Details
4/14/2008Q1 2008$6.49ViewN/AView Earnings Details
1/8/2008Q4 2007($4.69)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Lorus Therapeutics (NASDAQ:APTO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Lorus Therapeutics (NASDAQ APTO) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 1.17%
Insider Trading History for Lorus Therapeutics (NASDAQ:APTO)
Insider Trading History for Lorus Therapeutics (NASDAQ:APTO)

Lorus Therapeutics (NASDAQ APTO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Lorus Therapeutics (NASDAQ APTO) News Headlines

Source:
DateHeadline
Lorus Therapeutics (APTO) Lifted to Sell at ValuEngineLorus Therapeutics (APTO) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 19 at 11:32 AM
Zacks Investment Research Lowers Lorus Therapeutics (APTO) to HoldZacks Investment Research Lowers Lorus Therapeutics (APTO) to Hold
www.americanbankingnews.com - April 16 at 4:48 PM
Lorus Therapeutics (APTO) Given a $6.00 Price Target at HC WainwrightLorus Therapeutics (APTO) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 16 at 1:54 PM
Lorus Therapeutics (APTO) Given a $6.00 Price Target by Roth Capital AnalystsLorus Therapeutics (APTO) Given a $6.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - April 16 at 1:21 PM
-$0.12 Earnings Per Share Expected for Lorus Therapeutics, Inc. (APTO) This Quarter-$0.12 Earnings Per Share Expected for Lorus Therapeutics, Inc. (APTO) This Quarter
www.americanbankingnews.com - April 10 at 7:21 PM
Head-To-Head Survey: Lorus Therapeutics (APTO) versus Adverum Biotechnologies (ADVM)Head-To-Head Survey: Lorus Therapeutics (APTO) versus Adverum Biotechnologies (ADVM)
www.americanbankingnews.com - April 10 at 7:09 PM
Lorus Therapeutics (APTO) Upgraded to Buy at Zacks Investment ResearchLorus Therapeutics (APTO) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 6 at 5:52 PM
Lorus Therapeutics (APTO) "Buy" Rating Reiterated at Roth CapitalLorus Therapeutics' (APTO) "Buy" Rating Reiterated at Roth Capital
www.americanbankingnews.com - April 6 at 12:28 PM
Lorus Therapeutics (APTO) Downgraded to Hold at Zacks Investment ResearchLorus Therapeutics (APTO) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 5:46 PM
Lorus Therapeutics, Inc. (APTO) Receives Average Recommendation of "Hold" from BrokeragesLorus Therapeutics, Inc. (APTO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 5 at 1:21 AM
Lorus Therapeutics (APTO) Upgraded by ValuEngine to "Sell"Lorus Therapeutics (APTO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 4 at 12:02 AM
Lorus Therapeutics (APTO) Upgraded at ValuEngineLorus Therapeutics (APTO) Upgraded at ValuEngine
www.americanbankingnews.com - April 4 at 12:02 AM
Will Aptose Biosciences Inc’s (TSE:APS) Earnings Grow In The Next Couple Of Years?Will Aptose Biosciences Inc’s (TSE:APS) Earnings Grow In The Next Couple Of Years?
finance.yahoo.com - April 3 at 8:20 AM
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceAptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 3 at 8:20 AM
Lorus Therapeutics (APTO) Cut to "Hold" at Zacks Investment ResearchLorus Therapeutics (APTO) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 5:40 PM
Form SUPPL Aptose Biosciences Inc.Form SUPPL Aptose Biosciences Inc.
www.streetinsider.com - March 29 at 8:24 AM
ValuEngine Lowers Aptose Biosciences (APTO) to Strong SellValuEngine Lowers Aptose Biosciences (APTO) to Strong Sell
www.americanbankingnews.com - March 28 at 10:22 PM
Aptose Biosciences (APTO) Lifted to "Buy" at Zacks Investment ResearchAptose Biosciences (APTO) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 5:28 PM
Aptose Bio inks at-the-market stock sales agreement with CantorAptose Bio inks at-the-market stock sales agreement with Cantor
seekingalpha.com - March 28 at 5:20 PM
Aptose Biosciences (APTO) PT Set at $6.00 by HC WainwrightAptose Biosciences (APTO) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 11:01 AM
Windtree Therapeutics (WINT) & Aptose Biosciences (APTO) Head-To-Head ComparisonWindtree Therapeutics (WINT) & Aptose Biosciences (APTO) Head-To-Head Comparison
www.americanbankingnews.com - March 26 at 1:09 PM
Aptose Biosciences Inc (APTO) Expected to Post Earnings of -$0.11 Per ShareAptose Biosciences Inc (APTO) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - March 24 at 9:24 PM
Aptose Biosciences (APTO) Downgraded by Zacks Investment ResearchAptose Biosciences (APTO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM
Aptose Biosciences (APTO) Raised to "Buy" at Zacks Investment ResearchAptose Biosciences (APTO) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 5:56 PM
Aptose Biosciences (APTO) Upgraded to Sell at ValuEngineAptose Biosciences (APTO) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 13 at 11:28 PM
Aptose Biosciences Inc (APTO) Given Average Recommendation of "Hold" by AnalystsAptose Biosciences Inc (APTO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 11 at 1:38 AM
Form F-10/A Aptose Biosciences Inc.Form F-10/A Aptose Biosciences Inc.
www.streetinsider.com - March 8 at 5:25 PM
Aptose Biosciences (APTO) Reports Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM OncologyAptose Biosciences (APTO) Reports Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
www.streetinsider.com - March 8 at 9:32 AM
Aptose Biosciences (APTO) Given a $6.00 Price Target by HC Wainwright AnalystsAptose Biosciences (APTO) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 7 at 6:56 PM
 Analysts Anticipate Aptose Biosciences Inc (APTO) to Announce -$0.13 EPS Analysts Anticipate Aptose Biosciences Inc (APTO) to Announce -$0.13 EPS
www.americanbankingnews.com - March 7 at 3:18 PM
Aptose to Participate in Upcoming Investor Conferences In March 2018Aptose to Participate in Upcoming Investor Conferences In March 2018
feeds.benzinga.com - March 6 at 7:45 AM
Aptose Biosciences (APTO) Downgraded to "Strong Sell" at ValuEngineAptose Biosciences (APTO) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 5 at 12:12 AM
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
finance.yahoo.com - February 26 at 5:17 PM
Critical Survey: Aptose Biosciences (APTO) vs. Idera Pharmaceuticals (IDRA)Critical Survey: Aptose Biosciences (APTO) vs. Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - February 23 at 3:16 AM
Comparing Arena Pharmaceuticals (ARNA) and Aptose Biosciences (APTO)Comparing Arena Pharmaceuticals (ARNA) and Aptose Biosciences (APTO)
www.americanbankingnews.com - February 17 at 9:12 PM
Aptose Biosciences Inc (APTO) Given Average Rating of "Hold" by BrokeragesAptose Biosciences Inc (APTO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 14 at 1:28 AM
Aptose Biosciences (APTO) Upgraded to "Hold" by Zacks Investment ResearchAptose Biosciences (APTO) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - February 13 at 5:54 PM
BRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 MlnBRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln
www.reuters.com - February 8 at 3:28 PM
Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus - GlobeNewswire (press release)Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus - GlobeNewswire (press release)
globenewswire.com - February 8 at 7:01 AM
Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base ProspectusAptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus
finance.yahoo.com - February 8 at 7:01 AM
-$0.14 Earnings Per Share Expected for Aptose Biosciences Inc (APTO) This Quarter-$0.14 Earnings Per Share Expected for Aptose Biosciences Inc (APTO) This Quarter
www.americanbankingnews.com - February 1 at 11:22 PM
This Mornings Technical Outlook on Biotech Stocks -- Aptose Biosciences, Athersys, AVEO Pharma, and Aviragen ... - PR Newswire (press release)This Morning's Technical Outlook on Biotech Stocks -- Aptose Biosciences, Athersys, AVEO Pharma, and Aviragen ... - PR Newswire (press release)
www.prnewswire.com - February 1 at 7:24 AM
Reviewing Aptose Biosciences (APTO) and Repros Therapeutics (RPRX)Reviewing Aptose Biosciences (APTO) and Repros Therapeutics (RPRX)
www.americanbankingnews.com - January 29 at 3:08 PM
Aptose Biosciences Inc (APTO) Receives Average Recommendation of "Hold" from AnalystsAptose Biosciences Inc (APTO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 20 at 1:08 AM
Aptose Biosciences (APTO) Stock Rating Lowered by Zacks Investment ResearchAptose Biosciences (APTO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 16 at 6:02 PM
Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference - GlobeNewswire (press release)Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference - GlobeNewswire (press release)
globenewswire.com - January 2 at 8:52 PM
Aptose Biosciences to Present at Biotech Showcase™ 2018 ConferenceAptose Biosciences to Present at Biotech Showcase™ 2018 Conference
finance.yahoo.com - January 2 at 11:10 AM
Mid-Afternoon Market Update: Crude Oil Down 0.8%; Kazia ... - BenzingaMid-Afternoon Market Update: Crude Oil Down 0.8%; Kazia ... - Benzinga
www.benzinga.com - December 27 at 6:09 PM
Mid-Morning Market Update: Markets Mostly Lower; Mallinckrodt To Buy Sucampo Pharmaceuticals For $18/Share - BenzingaMid-Morning Market Update: Markets Mostly Lower; Mallinckrodt To Buy Sucampo Pharmaceuticals For $18/Share - Benzinga
www.benzinga.com - December 26 at 3:23 PM
Mid-Afternoon Market Update: Crude Oil Up 2.5%; Aptose Biosciences Shares Spike Higher - BenzingaMid-Afternoon Market Update: Crude Oil Up 2.5%; Aptose Biosciences Shares Spike Higher - Benzinga
www.benzinga.com - December 26 at 3:23 PM

SEC Filings

Lorus Therapeutics (NASDAQ:APTO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Lorus Therapeutics (NASDAQ:APTO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Lorus Therapeutics (NASDAQ APTO) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.